IVERIC bio Stock Soars After Encouraging Geographic Atrophy Trial Data

IVERIC bio Inc ISEE announced positive data from the second Phase 3 trial of Zimura (avacincaptad pegol) for geographic atrophy (GA). 

GATHER2 met its prespecified primary endpoint of mean growth rate (slope) in GA area at 12 months with statistical significance and a favorable safety profile.

Zimura showed a 14.3% reduction in the mean growth rate (slope) in GA area over 12 months using square root transformation and a 17.7% reduction using the observed GA area.

Post-hoc Analysis of U.S. Patients showed a 25.5% reduction and 32.0%, respectively.

In GATHER2, there were no events of endophthalmitis, no intraocular inflammation events, and ischemic optic neuropathy events. The most frequently reported ocular adverse events were related to the injection procedure.

Zimura 2 mg reduced all analyzed subgroups' mean growth rate (slope) in the GA area.

For best corrected visual acuity, a favorable trend for Zimura 2 mg was observed consistent with GATHER1. A favorable trend was not observed for low luminance best corrected visual acuity.

The company plans to submit a marketing application to the FDA by the end of Q1 2023.

Price Action: ISEE shares are up 42% at $13.40 during the premarket session on the last check Tuesday.

Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...